We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0A8D market cap is 0. The company's latest EPS is USD -0.1615 and P/E is -11.27.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.58M | 0 | 0 | 0 | 0 |
| Operating Income | -3.98M | -12.29M | -28.2M | -15.28M | -17.12M |
| Net Income | -3.89M | -17.58M | -29.89M | -15.2M | -8.22M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 10.89M | 36.84M | 24.81M | 17.54M | 17.86M |
| Total Liabilities | 1.53M | 2.26M | 1.17M | 2.85M | 5.09M |
| Total Equity | 9.36M | 34.58M | 23.65M | 14.7M | 12.37M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -3.07M | -11.93M | -19.52M | -12.27M | -12.98M |
| Investing | -3.94M | -8.76M | 19.85M | 6.91M | 1.85M |
| Financing | 6.97M | 38.67M | 74k | 5.55M | 13.07M |
| Market Cap | 0 |
| Price to Earnings Ratio | -11.27 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 34.54 |
| Price to Book Ratio | 7.25 |
| Dividend Yield | - |
| Shares Outstanding | 50.9M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Tnf Pharmaceuticals Inc |
| Address |
855 n. wolfe street baltimore, maryland 21205 |
| Website | https://www.mymd.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
